Our team of breast cancer experts is dedicated to improving clinical care and advancing research for patients with ductal carcinoma in situ (DCIS). Our physician-scientists are engaged in multiple research studies to better understand the risk of progression to invasive disease and to better tailor treatment options to meet the needs of patients with DCIS.
Patients at Dana-Farber have access to leading-edge research and the opportunity to join clinical trials. Your team will discuss whether a clinical trial may be right for you. Together, we will advance the understanding of DCIS in order to provide more personalized treatment and prevention strategies for patients now and in the future.
Featured Clinical Trials
The PREDICT Registry
The primary objective of this study is to create a de-identified database of patients, test results, treatment decisions, and outcomes that can be queried to determine the clinical utility of the DCISionRT™ Test in the management of DCIS, as it is broadly incorporated into clinical practice.
Principal investigator: Elizabeth Mittendorf, MD, PhD
Trial 24-500: RENAISSANCE: Refining tamoxifen dose for premenopausal breast cancer risk reduction – a phase 2 single arm trial
Principal investigator: Judy Garber, MD, MPH
Trial 23-676: Resistance and aerobic exercise for prevention in women with dense breasts
Principal investigator: Jennifer Ligibel, MD
Trial 22-351: Randomized 2B study of the effect of bazedoxifene plus conjugated estrogens on breast imaging and tissue biomarkers in peri- or post-menopausal women at increased risk for development of breast cancer
Principal investigator: Judy Garber, MD, MPH